The Total Point of Care Diagnositcs Market will Reach $20.9bn in 2015', Says Visiongain Report

LONDON, May 7, 2013 /PRNewswire/ --

A new report by visiongain, a London-based business information provider, predicts that the global point of care coagulation testing market will be worth $1.8bn by 2017. The market generated $1.0bn in 2011, according to Point of Care Coagulation Testing: World Market 2013-2023, published in April 2013.

Point of care (POC) coagulation testing constitutes one of the fastest-growing markets in the POC diagnostics market. As the name suggests, POC diagnostics are diagnostic tests that are conducted at or near the site of patient care. The use of these tests can provide faster results, helping improve patient management. There are already a number of POC diagnostics in the market, with many more in development. There are some challenges to meet, and the opportunity for growth in this market is vast.

Rupali Vadhera, a healthcare industry analyst in visiongain says: "The point of care coagulation testing market will experience growth in the next 10 years, primarily due to the introduction of new devices and patient demand for rapid diagnostics. Improvement in technology and accuracy of the POC tests will also help drive growth in the coming years. The launch of new anticoagulant drugs, which do not require testing for coagulation, will restrain growth beyond 2017. However, growth will be driven by the increasing use of anticoagulant therapy and higher adoption of self-testing kits for use at home.

"For the past several years, four companies - Roche, International Technidyne Corporation (ITC), Abbott, and Alere - have dominated the POC PT/INR testing market. The devices currently available in the market are able to meet demand. However, there is need for improvement in technology to attract more physicians and patients to use this testing. Most of the testing for patients on anticoagulant warfarin is currently conducted in laboratories. Such patients need regular monitoring. The use of POC tests can help save a lot of time and money spent on unwanted complications arising from the use of the drug without monitoring".

Visiongain predicts the POC coagulation testing market will grow steadily to 2023. The future of the global market appears promising and has significant potential for growth and investment, with increasing demand for rapid tests and self management of conditions by patients.

Visiongain's report gives revenue forecasts to 2023 at overall world market, submarket and national level. It forecasts world sales for the following segments:

• Point of care diagnostics
• Point of care coagulation testing (including PT/INR testing)
• Anticoagulant drug market

That study also analyses leading companies including Roche, International Technidyne Corporation (ITC) and Abbott. The study includes researching trends and forecasting revenues in leading national markets. The analysis discusses opportunities and developments - technological and commercial.

Point of Care Coagulation Testing: World Market 2013-2023 adds to visiongain's range of analytical reports on industries and markets in healthcare and other industries.

For sample pages and further information concerning the visiongain report Point of Care Coagulation Testing: World Market 2013-2023 please visit

http://www.visiongain.com/Report/1037/Point-of-Care-Coagulation-Testing-World-Market-2013-2023

For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com

Tel: +44 (0) 20 7336 6100

Companies Listed

Abbott
AbbVie
Alere
AntiCoagulation Europe
AntiCoagulation Self-Monitoring Alliance (ACSMA)
Atrial Fibrillation Association
Barr Pharmaceuticals
Bayer
Baylor College of Medicine [US]
Bio-AMD
Boehringer Ingelheim
Centers for Device and Radiological Health (CDRH) [US]
Centers for Disease Control and Prevention (CDC) [US]
Centers for Medicare & Medicaid Services (CMS) [US]
Children's Heart Federation
Chugai Pharmaceuticals
CoaguSense
College of American Pathologists
EIDIA
Eisai
Entegrion
European Commission
European Diagnostics Manufacturers Association (EDMA)
Food and Drug Administration (FDA) [US]
Genentech
GlaxoSmithKline
Helena Laboratories
Ibis Biosciences
Instrumentation Laboratory
International Self-Monitoring Association of Oral Anticoagulated Patients (ISMAAP)
International Technidyne Corporation
La Federación Española de Asociaciones de Anticoagulados (FEASAN)
Mechanical Heart Valve Support Group
Medtronic
Merck
Ministry of Health, Labor and Welfare (MHLW) [Japan]
Mount Sinai School of Medicine
National Health Service (NHS) [UK]
Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)
Portola Pharmaceuticals
QuickMedical
Roche
Siemens
STARLIMS Technologies
Suyog Diagnostics
Teva
Thermo Cardiosystems
Thermo Electron Corporation
Thoratec Corporation
Transasia Bio-Medicals
Universal Biosensor (UBI)
US Department of Defense (DoD)
Ventana
Warburg Pincus
Werfen Group
World Health Organization (WHO)

Notes for Editors



About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Automotive and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44-(0)207-336-6100